BPC-157 and cancer: what the evidence shows

The short answer: no study has shown that BPC-157 causes cancer or makes an existing cancer grow, and no study has ruled it out either. The concern is theoretical. In rat and cell experiments, BPC-157 promotes new blood vessel growth and raises levels of VEGFR2, a growth factor receptor that tumors also depend on. [1] FDA's July 2026 review found no carcinogenicity studies of BPC-157 at all. [2] No human study has assessed cancer risk, and the published human record covers about 30 people. [3]

So the precise description is "theoretical, unstudied in humans," not "proven safe" and not "causes cancer." That is why our BPC-157 record lists active cancer or a history of cancer as a contraindication. This page explains where the concern comes from, what the few tumor experiments found in both directions, and what FDA's reviewers said. It is not medical advice, and it does not give dosing.

Why would BPC-157 raise a cancer concern?

Because of angiogenesis, the growth of new blood vessels. It is one of the main ways BPC-157 is thought to work, and it is also how tumors feed themselves.

The clearest evidence comes from a group in Taiwan that does not include the Zagreb laboratory that discovered BPC-157. BPC-157 increased blood vessel density in a chick embryo membrane assay, sped blood flow recovery and raised vessel counts in rats with a blocked leg artery, and increased VEGFR2 in rat muscle and in human vascular endothelial cells (the cells that line blood vessels). It also switched on the VEGFR2 to Akt to eNOS signaling chain. Notably, it raised the receptor, not VEGF-A, the growth factor that binds to it. [1] A separate study found that BPC-157 increased the growth, migration, and tube formation of human endothelial cells in culture and raised VEGF-A in healing rat skin. [4] These effects are the reason BPC-157 is studied for wound healing and tendon injuries.

The same machinery matters in cancer. In 1971 Judah Folkman proposed that solid tumors cannot grow much beyond a small size without recruiting new blood vessels. [5] That idea became a foundation of cancer biology, and VEGF signaling is central to it. [6] VEGFR2 is a proven cancer drug target: in a randomized, placebo-controlled phase 3 trial, ramucirumab, an antibody that blocks VEGFR2, extended survival in advanced gastric cancer, and the authors concluded the result validated VEGFR2 signaling as a therapeutic target. [7]

Put together, the worry is simple: a substance that increases VEGFR2 signaling could, in theory, help an existing tumor build its blood supply. An independent 2025 review made this argument and added that BPC-157's effects on nitric oxide and the EGR-1 gene also have documented links to tumor growth. It noted that angiogenesis is normal in healthy people too, for example in muscle growth, and concluded that BPC-157 may not be the right choice when a person could have cancer cells they are unaware of. [8] A 2026 clinical review listed pathological angiogenesis and carcinogenesis among the potential risks of unapproved injectable peptides, including BPC-157. [9]

None of this is a finding that BPC-157 caused or worsened a cancer. It is a mechanism-based reason to ask the question.

What did FDA say about BPC-157 and cancer?

FDA said the data do not exist. Its briefing document for the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting has a carcinogenicity section with one finding: the nominator did not submit, and FDA did not identify, any carcinogenicity study of BPC-157 or its acetate salt. FDA explains that such studies are normally run for drugs expected to be used continuously or intermittently for 6 months or more. [2]

The same review summarized what is known:

• Genotoxicity: negative. In a bacterial mutation test, a chromosome aberration test in hamster cells, and a mouse bone marrow micronucleus test, BPC-157 did not cause DNA damage, and FDA concluded it is not a mutagen. [2] [10] That speaks to whether a substance can start a cancer by damaging DNA. It does not test whether a substance speeds the growth of a tumor that is already there, which is the angiogenesis concern.
• Mechanism: unclear. FDA listed angiogenesis among the mechanisms researchers propose for BPC-157, but noted that its molecular targets have not been identified and its mechanisms remain poorly understood. [2]
• Toxicology: short. The longest repeat-dose animal studies lasted 28 days. FDA read them as showing possible clotting and liver signals and said longer studies were unavailable to show whether those signals persist or new ones emerge. [2]

FDA's presentation slides concluded that there is insufficient clinical safety information to characterize BPC-157's safety profile, flagged a risk of immune reactions, and recommended against adding it to the 503A bulks list. [15]

FDA's earlier rationale for placing BPC-157 in 503A Category 2 did not mention tumors. It cited possible immune reactions, peptide impurities, and too little safety information to know whether it would cause harm in people. [11] By contrast, FDA's entry for another peptide on the same page, LL-37, cites nonclinical findings that it can be protumorigenic in some tissues. [11] For BPC-157, FDA's concern is missing data, not a tumor finding.

What have tumor studies of BPC-157 actually found?

Very little, and nothing that shows tumor promotion. A 2025 review found no published study relating BPC-157 directly to cancer, apart from one on cancer-related wasting. [8]

1. Colon cancer cachexia in mice, 2018. Researchers in Korea, with a co-author from the Zagreb group, gave BPC-157 to mice with implanted colon adenocarcinoma cells, a standard model of cancer cachexia (muscle and weight loss caused by cancer), and proposed it as a candidate treatment. [12] According to an independent review of the study, treated mice kept more body weight and had lower inflammatory markers (IL-6 and TNF-alpha), and their tumors were smaller but not by a statistically significant margin. That review read the result as no meaningful effect on tumor size. [8] The Zagreb group's own 2025 review describes the same study as showing markedly longer survival. [13]

2. A melanoma cell line. The Zagreb group's 2025 review cites a report that BPC-157 inhibited growth and VEGF signaling in a human melanoma cell line, and describes unpublished mouse data with fewer lung metastases. On that basis the authors argue that BPC-157 regulates angiogenesis rather than simply increasing it, and that it has anti-tumor potential. [13] We could not find the melanoma cell study as a full paper indexed in PubMed, and unpublished data cannot be checked. These are also the researchers who discovered and have long developed the compound.

3. Standard animal safety studies. In single-dose and repeat-dose studies in mice, rats, rabbits, and dogs, BPC-157 was well tolerated and caused no serious toxicity. [10] None of these studies was designed or long enough to detect cancer.

What is missing matters more than what is there: no lifetime rodent carcinogenicity study, no independent study of tumor-bearing animals designed to look for faster growth or spread, and no replication of the anti-tumor claims. The honest reading is that the animal data neither show that BPC-157 promotes tumors nor convincingly show that it protects against them.

Has any human study looked at BPC-157 and cancer?

No. The entire published human record is three small uncontrolled pilot reports, together describing about 30 people, on knee pain, interstitial cystitis, and intravenous safety. [3] A 2025 systematic review found no clinical safety data at all. [14] We list every report in BPC-157 human studies.

Detecting a cancer effect would take large groups followed for years. When FDA searched its adverse event database, it found three reports involving BPC-157, none of them cancer, and said it could not tell whether BPC-157 caused the problems reported. [15] An absence of cancer reports in this record is not evidence of safety; it reflects how little has been studied.

Who does the cancer caution apply to?

Our record lists "active cancer or history of cancer" as a contraindication, labeled as a theoretical angiogenesis concern. [1] In practice that covers:

• People with active cancer, including anyone in treatment, because the theoretical concern is about helping an existing tumor grow.
• People with a past cancer, including those in remission, because cancer cells can persist undetected.
• Anyone who could have an undiagnosed cancer. This is the point the 2025 review made, and it is one reason reviewers say BPC-157 should be treated as investigational and approached with caution. [3] [8]

Pregnancy, breastfeeding, and competitive sport are also on the contraindication list, for different reasons. If you have a cancer history, talk to a licensed clinician, ideally your oncologist, before using any unapproved peptide, and tell your care team about anything you have already taken.

Is BPC-157 safe apart from the cancer question?

Unknown. Animal toxicity studies were reassuring in the short term, but FDA saw possible clotting and liver signals, flagged a risk of immune reactions, and found too little human data to characterize safety. [10] [15] Products sold outside pharmacies add a separate risk: what is in the vial, how much, and whether it is sterile are not verified. [9] Our guide to whether peptide injections are safe covers those product risks in detail.

Where does BPC-157 stand legally?

BPC-157 is not an FDA approved drug. In April 2026 FDA moved it from 503A Category 2 to a list of nominations withdrawn by their nominators, which places it in no 503A category and outside FDA's interim policy. [11] FDA presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026 and proposed that it not be added to the 503A bulks list. [15] News reports said the committee voted to recommend listing it, but FDA has not posted the vote or minutes and has proposed no rule. It is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk. [16] WADA prohibits it at all times under section S0. [17]

Follow dated changes on the BPC-157 regulatory timeline and check your state in our legal guides. Until a carcinogenicity study, independent tumor experiments, or long-term controlled human trials exist, the cancer question stays open.